Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 476

Sort by

Sort Order Select

Journal Articles

Effectiveness of Prophylaxis with Granulocyte Colony-Stimulating Factor Among Cancer Patients Receiving Myelosuppressive Chemotherapy in US Clinical Practice

Kathryn Richert-Boe, MD MPH, Lois Lamerato, PhD, Gary H. Lyman, MD MPH, Manpreet Kaur, MPH, MBA, Neel Shah, BPharm, PhD, Tatiana Lawrence, MD, Devi Sundaresan, MS, Amanda Silvia, BS, Ahuva Hanau, BS, Derek Weycker, PhD

Blood (2019) 134 (Supplement_1): 4688.

https://doi.org/10.1182/blood-2019-123559

Published: 2019

Journal Articles

Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

Blood (2019) 134 (Supplement_1): 864.

https://doi.org/10.1182/blood-2019-131476

Published: 2019

Journal Articles

Retrospective Comparison between MEC and FLAG-Ida Regimens for Refractory or Relapsed Acute Myeloid Leukemia in Adults

Wellington F Silva, MD, Lidiane Inês Da Rosa, MD, Fernanda S Seguro, MD, Douglas R. A. Silveira, Luciana Nardinelli, M.Sc, Valeria Buccheri, MD PhD, Elvira DRP Velloso, MD PhD, Vanderson Rocha, MD PhD, Eduardo M Rego, MD PhD

Blood (2019) 134 (Supplement_1): 1354.

https://doi.org/10.1182/blood-2019-127202

Published: 2019

Journal Articles

Antibody Dependent Enhancement of Infections after High Dose Chemotherapy

Jens Magnus Bernth-Jensen, MD, Bjarne Kuno Møller, MD, Steffen Thiel, PhD, Anette Tarp Hansen, MD PhD

Blood (2019) 134 (Supplement_1): 1047.

https://doi.org/10.1182/blood-2019-122236

Published: 2019

Journal Articles

Feasibility of Peripheral Blood Stem Cell Collection from Heterozygoussickle Cell Trait Donors

Juergen Foell, MD, Morad Morez, Anja Troeger, MD, Katharina Kleinschmidt, MD PhD, Beatrix Pfirstinger, Andreas Brosig, MD PhD, Ralph Burkhardt, MD PhD, Selim Corbacioglu, MD, Norbert Ahrens

Blood (2019) 134 (Supplement_1): 1171.

https://doi.org/10.1182/blood-2019-131984

Published: 2019

Journal Articles

Filgrastim Administered after Early Assessment Bone Marrow Biopsy during 7+3 Induction Therapy for Acute Myeloid Leukemia Reduces Length of Hospital Stay

Jiasheng Wang, MD, Kirsten M Boughan, DO, Paolo F Caimi, MD, Brenda Cooper, MD, Marcos de Lima, MD, Molly M Gallogly, MD PhD, Ehsan Malek, MD, Leland Metheny, III, MD, Folashade Otegbeye, MBBChir,MPH, Shufen Cao, Pingfu Fu, PhD, Benjamin Tomlinson, MD

Blood (2019) 134 (Supplement_1): 2607.

https://doi.org/10.1182/blood-2019-131293

Published: 2019

Journal Articles

Comparison of Early Versus Delayed Filgrastim (G-CSF) Administration Following Autologous Stem Cell Transplantation in Patients with Multiple Myeloma - Real-World Data from a Single-Center Institution

Blood (2019) 134 (Supplement_1): 5644.

https://doi.org/10.1182/blood-2019-130914

Published: 2019

Journal Articles

Potential and Realized Cost Savings with the Use of the Biosimilar Grastofil Vs Neupogen

Hishaam Bhimji, BSP, Dean Eurich, PhD, Kerry Mansell, PharmD, MBA, Holly Mansell, PharmD

Blood (2019) 134 (Supplement_1): 2126.

https://doi.org/10.1182/blood-2019-122751

Published: 2019

Journal Articles

Lower Hematopoietic Progenitor Cell Counts and Yields at Subsequent Donations Is Influenced By a Shorter Inter-Donation Interval between the First and Subsequent Mobilizations

Sandhya R. Panch, MDMPH, Brent R. Logan, Jennifer A. Sees, MPH, Bipin N. Savani, MD, Nirali N. Shah, MD, Jack W. Hsu, MD, Michael A. Pulsipher, MD, Galen E. Switzer, PhD, Bronwen E. Shaw, MD PhD, David F. Stroncek, MD

Blood (2019) 134 (Supplement_1): 1962.

https://doi.org/10.1182/blood-2019-123492

Published: 2019

Journal Articles

Dose-Adjusted Granulocyte Colony-Stimulating Factor Plus Dexamethasone Achieves More CD34+ Cell Mobilization and Earlier Engraftment in Haploidentical Hematopoietic Stem Cell Transplantation

Chenglong Li, MDand PhD, Xi Yang, Jingying Dai, PhD, Ningning Tang, Hong Zheng, MD PhD, Chunsen Wang, MD, Xiaobing Huang

Blood (2019) 134 (Supplement_1): 1966.

https://doi.org/10.1182/blood-2019-126632

Published: 2019

Journal Articles

An Evaluation of Major Comorbidities and Treatment Patterns of Newly Diagnosed Acute Myeloid Leukemia Patients: A Retrospective Analysis of Electronic Medical Records from US

Nora Tu, PhD, Zahidul Islam, MPH, Albert E Fliss, PhD, Maribel Salas, MD DSc, MSc

Blood (2019) 134 (Supplement_1): 5106.

https://doi.org/10.1182/blood-2019-124517

Published: 2019

Journal Articles

Incorporating Reduced-Dose Plerixafor to a Preemptive Mobilization Algorithm Increases Access to Autologous Transplantation in a Limited-Resource Setting

Andrés Gómez-De León, MD, Dalila Marisol Alvarado Navarro, MD, Cesar O Pezina Cantú, MD, Perla R. Colunga Pedraza, MD, David Gomez-Almaguer, MD, Rosario Salazar Riojas, Chem., Olga Graciela Cantu Rodriguez, MD, Luz del Carmen Tarín Arzaga, MD, Jose Carlos Jaime, MD PhD, Cesar Homero Gutierrez-Aguirre, PhD

Blood (2019) 134 (Supplement_1): 4476.

https://doi.org/10.1182/blood-2019-129516

Published: 2019

Journal Articles

CBFA2T3-GLIS2 Fusion Gene Cause Dismal Clinical Course in Acute Megakaryocytic Leukemia of Down Syndrome

Nao Takasugi, Kenichi Amano, Yasuo Kubota, MD, Shota Kato, MD, Yuichi Mitani, MD, Junya Fujimura, MD PhD, Junko Takita, MD PhD, Mitsuteru Hiwatari, MD PhD

Blood (2019) 134 (Supplement_1): 5184.

https://doi.org/10.1182/blood-2019-129165

Published: 2019

Journal Articles

Outcomes of Primary and Secondary Prophylaxis of Chemotherapy Induced and Febrile Neutropenia (CIN/FN) in Bendamustine Plus Rituximab (BR) Regimens in Patients with Lymphoma and Chronic Lymphocytic Leukemia (CLL): Real-World, Single-Center Experience

Logan Moore, Trace Bartels, BS, Daniel O. Persky, MD, Abhijeet Kumar, Ivo Abraham, PhD RN, Lauren Sanders, PharmD, Alicia Ortega, PharmD, Alyssa Henglefelt, PharmD, Ali McBride, PharmD,MS

Blood (2019) 134 (Supplement_1): 5353.

https://doi.org/10.1182/blood-2019-132148

Published: 2019

Journal Articles

Toxicity of a Modified Peg-Asparaginase-Based SMILE Regimen Is Comparable to L-Asparaginase-Based SMILE in a Non-Asian Population

Ryan J Caddell, PharmD, BCOP, Hayder Saeed, MD, Rebecca Nelson, PharmD, BCOP, Leidy Isenalumhe, MD, Julio Chavez, Celeste Bello, MD, Javier Pinilla Ibarz, MD PhD, Lubomir Sokol, MD PhD, Bijal Shah, MD

Blood (2019) 134 (Supplement_1): 5292.

https://doi.org/10.1182/blood-2019-128435

Published: 2019

Journal Articles

Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma: No Impairment in Stem Cell Mobilization or Engraftment

Locke J. Bryan, MD, Scott E. Smith, MD PhD, Pamela Allen, MDMSc, Carla Casulo, Brett Alan Palmer, BS, Reem Karmali, MD, Barbara Pro, MD, Denise M Scholtens, PhD, Hatice Savas, MD, Jayesh Mehta, MD, Leo I. Gordon, MD, Jane N. Winter, MD

Blood (2019) 134 (Supplement_1): 4029.

https://doi.org/10.1182/blood-2019-123879

Published: 2019

Journal Articles

A Phase Ib/II Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML

Iman Aboudalle, MD, Marina Y Konopleva, MD PhD, Tapan M. Kadia, MD, Kiran Naqvi, MDMPH, Kenneth Vaughan, RN, Mehmet Kurt, RN, Antonio Cavazos, Sherry A. Pierce, BSN, BA, Koichi Takahashi, MD, Lucia Masarova, MD, Musa E. Yilmaz, MD, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Steven M. Kornblau, MD, Farhad Ravandi, MD, Jorge Cortes, MD, Hagop M. Kantarjian, MD, Courtney D. DiNardo, MD MSc

Blood (2019) 134 (Supplement_1): 176.

https://doi.org/10.1182/blood-2019-121780

Published: 2019

Journal Articles

Prophylactic Use of Filgrastim on Days 7, 11 and 14 in Patients Receiving R-CHOP for Non-Hodgkin's Lymphoma

Sherief El- Shakankery, MPharm, Sumantha Gabriel, BPharm, Emma Groves, M Pharm

Blood (2019) 134 (Supplement_1): 5887.

https://doi.org/10.1182/blood-2019-124329

Published: 2019

Journal Articles

Primary Prophylaxis with Pegfilgrastim in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Nation-Wide, Propensity Score Based Analysis

Kensuke Matsuda, MD, Taisuke Jo, Masashi Miyauchi, MD PhD, Kazuhiro Toyama, MD PhD, Kumi Nakazaki, Hideo Yasunaga, MD PhD, Mineo Kurokawa, MD PhD

Blood (2019) 134 (Supplement_1): 1605.

https://doi.org/10.1182/blood-2019-123611

Published: 2019

Journal Articles

Cost Simulation for Febrile Neutropenia Hospitalization in the US Due to Pegfilgrastim on-Body Injector Failure Compared to Single-Injection Pegfilgrastim and Daily Injections with Reference and Biosimilar Filgrastim in Non-Hodgkin Lymphoma

Ali McBride, PharmD,MS, Andriy Krendyukov, MD MBA, Nicola Mathieson, Kim Campbell, PharmD, Sanjeev Balu, PhD, Karen MacDonald, PhD, Ivo Abraham, PhD RN

Blood (2018) 132 (Supplement 1): 2251.

https://doi.org/10.1182/blood-2018-99-116315

Published: 2018

NARROW

Effectiveness of Prophylaxis with Granulocyte Colony-Stimulating Factor Among Cancer Patients Receiving Myelosuppressive Chemotherapy in US Clinical Practice

Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

Retrospective Comparison between MEC and FLAG-Ida Regimens for Refractory or Relapsed Acute Myeloid Leukemia in Adults

Antibody Dependent Enhancement of Infections after High Dose Chemotherapy

Feasibility of Peripheral Blood Stem Cell Collection from Heterozygoussickle Cell Trait Donors

Filgrastim Administered after Early Assessment Bone Marrow Biopsy during 7+3 Induction Therapy for Acute Myeloid Leukemia Reduces Length of Hospital Stay

Comparison of Early Versus Delayed Filgrastim (G-CSF) Administration Following Autologous Stem Cell Transplantation in Patients with Multiple Myeloma - Real-World Data from a Single-Center Institution

Potential and Realized Cost Savings with the Use of the Biosimilar Grastofil Vs Neupogen

Lower Hematopoietic Progenitor Cell Counts and Yields at Subsequent Donations Is Influenced By a Shorter Inter-Donation Interval between the First and Subsequent Mobilizations

Dose-Adjusted Granulocyte Colony-Stimulating Factor Plus Dexamethasone Achieves More CD34+ Cell Mobilization and Earlier Engraftment in Haploidentical Hematopoietic Stem Cell Transplantation

An Evaluation of Major Comorbidities and Treatment Patterns of Newly Diagnosed Acute Myeloid Leukemia Patients: A Retrospective Analysis of Electronic Medical Records from US

Incorporating Reduced-Dose Plerixafor to a Preemptive Mobilization Algorithm Increases Access to Autologous Transplantation in a Limited-Resource Setting

CBFA2T3-GLIS2 Fusion Gene Cause Dismal Clinical Course in Acute Megakaryocytic Leukemia of Down Syndrome

Outcomes of Primary and Secondary Prophylaxis of Chemotherapy Induced and Febrile Neutropenia (CIN/FN) in Bendamustine Plus Rituximab (BR) Regimens in Patients with Lymphoma and Chronic Lymphocytic Leukemia (CLL): Real-World, Single-Center Experience

Toxicity of a Modified Peg-Asparaginase-Based SMILE Regimen Is Comparable to L-Asparaginase-Based SMILE in a Non-Asian Population

Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma: No Impairment in Stem Cell Mobilization or Engraftment

A Phase Ib/II Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML

Prophylactic Use of Filgrastim on Days 7, 11 and 14 in Patients Receiving R-CHOP for Non-Hodgkin's Lymphoma

Primary Prophylaxis with Pegfilgrastim in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Nation-Wide, Propensity Score Based Analysis

Cost Simulation for Febrile Neutropenia Hospitalization in the US Due to Pegfilgrastim on-Body Injector Failure Compared to Single-Injection Pegfilgrastim and Daily Injections with Reference and Biosimilar Filgrastim in Non-Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only